C
Claudia S. Moy
Researcher at National Institutes of Health
Publications - 83
Citations - 17716
Claudia S. Moy is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Stroke & Population. The author has an hindex of 46, co-authored 83 publications receiving 15506 citations. Previous affiliations of Claudia S. Moy include Centers for Disease Control and Prevention & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Heart Disease and Stroke Statistics—2013 Update A Report From the American Heart Association
Alan S. Go,Dariush Mozaffarian,Véronique L. Roger,Emelia J. Benjamin,Jarett D. Berry,William B. Borden,Dawn M. Bravata,Shifan Dai,Earl S. Ford,Caroline S. Fox,Sheila Franco,Heather J. Fullerton,Cathleen Gillespie,Susan M. Hailpern,John A. Heit,Virginia J. Howard,Mark D. Huffman,Brett M. Kissela,Steven J. Kittner,Daniel T. Lackland,Judith H. Lichtman,Lynda D. Lisabeth,David J. Magid,Gregory M. Marcus,Ariane Marelli,David B. Matchar,Darren K. McGuire,Emile R. Mohler,Claudia S. Moy,Michael E. Mussolino,Graham Nichol,Nina P. Paynter,Pamela J. Schreiner,Paul D. Sorlie,Joel Stein,Tanya N. Turan,Salim S. Virani,Nathan D. Wong,Daniel Woo,Melanie B. Turner +39 more
TL;DR: Author(s): Go, Alan S; Mozaffarian, Dariush; Roger, Veronique L; Benjamin, Emelia J; Berry, Jarett D; Borden, William B; Bravata, Dawn M; Dai, Shifan; Ford, Earl S; Fox, Caroline S; Franco, Sheila; Fullerton, Heather J; Gillespie, Cathleen; Hailpern, Susan M; Heit, John A; Howard, Virginia J; Huff
Journal ArticleDOI
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial
Frances M. Weaver,Frances M. Weaver,Kenneth A. Follett,Matthew B. Stern,Matthew B. Stern,Kwan Hur,Crystal L. Harris,William J. Marks,William J. Marks,Johannes C. Rothlind,Johannes C. Rothlind,Oren Sagher,Domenic J. Reda,Claudia S. Moy,Rajesh Pahwa,Kim J. Burchiel,Kim J. Burchiel,Penelope Hogarth,Penelope Hogarth,Eugene C. Lai,Eugene C. Lai,John E. Duda,John E. Duda,Kathryn L. Holloway,Kathryn L. Holloway,Ali Samii,Stacy Horn,Jeff M. Bronstein,Gatana Stoner,Jill Heemskerk,Grant D. Huang +30 more
TL;DR: Deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events.
Journal ArticleDOI
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.
Kenneth A. Follett,Kenneth A. Follett,Frances M. Weaver,Matthew B. Stern,Kwan Hur,Crystal L. Harris,Ping Luo,William J. Marks,Johannes C. Rothlind,Oren Sagher,Claudia S. Moy,Rajesh Pahwa,Kim J. Burchiel,Kim J. Burchiel,Penelope Hogarth,Eugene C. Lai,John E. Duda,Kathryn L. Holloway,Ali Samii,Stacy Horn,Jeff M. Bronstein,Gatana Stoner,Philip A. Starr,Richard K. Simpson,Gordon H. Baltuch,Antonio A.F. De Salles,Grant D. Huang,Domenic J. Reda +27 more
TL;DR: Patients with Parkinson's disease had similar improvement in motor function after either pallidal or subthalamic stimulation, and nonmotor factors may reasonably be included in the selection of surgical target for deep-brain stimulation.
Journal ArticleDOI
Cognition assessment using the NIH Toolbox
Sandra Weintraub,Sureyya Dikmen,Robert K. Heaton,David S. Tulsky,Philip David Zelazo,Patricia J. Bauer,Noelle E. Carlozzi,Jerry Slotkin,David L. Blitz,Kathleen Wallner-Allen,Nathan A. Fox,Jennifer L. Beaumont,Dan M Mungas,Cindy J. Nowinski,Jennifer Richler,Joanne Deocampo,Jacob E. Anderson,Jennifer J. Manly,Beth Borosh,Richard Havlik,Kevin P. Conway,Emmeline Edwards,Lisa S. Freund,Jonathan W. King,Claudia S. Moy,Ellen D. Witt,Richard Gershon +26 more
TL;DR: The NIH-TB Cognition Battery is intended to serve as a brief, convenient set of measures to supplement other outcome measures in epidemiologic and longitudinal research and clinical trials and will provide a “common currency” among researchers for comparisons across a wide range of studies and populations.
Journal ArticleDOI
Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial
Jay P. Mohr,Michael K. Parides,Christian Stapf,Christian Stapf,Ellen Moquete,Claudia S. Moy,Jessica Overbey,Rustam Al-Shahi Salman,Eric Vicaut,William L. Young,Emmanuel Houdart,Charlotte Cordonnier,Marco Antonio Stefani,Andreas Hartmann,Rüdiger von Kummer,Alessandra Biondi,Joachim Berkefeld,Catharina J.M. Klijn,Kirsty Harkness,Richard B. Libman,Xavier Barreau,Alan J. Moskowitz +21 more
TL;DR: The ARUBA trial showed that medical management alone is superior to medical management with interventional therapy for the prevention of death or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months.